Abeona Therapeutics (ABEO) Change in Accured Expenses (2011 - 2026)

Abeona Therapeutics' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at -$7.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 207.61% year-over-year to -$7.3 million; the TTM figure through Mar 2026 stood at -$5.0 million (down 647.32% YoY), while the FY2025 annual figure was -$85000.0, down 631.25% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$7.3 million, down from -$23000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.8 million in Q4 2022, with the low at -$7.3 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1000.0 (2023), against an average of -$375666.7.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 152.81% in 2023, then tumbled 169100.0% in 2024.
• Abeona Therapeutics' Change in Accured Expenses stood at $4.8 million in 2022, then plunged by 73.54% to $1.3 million in 2023, then sank by 83.11% to $216000.0 in 2024, then plunged by 110.65% to -$23000.0 in 2025, then plunged by 31704.35% to -$7.3 million in 2026.
• Business Quant data shows ABEO's Change in Accured Expenses at -$7.3 million in Q1 2026, -$23000.0 in Q4 2025, and $2.3 million in Q2 2025.